Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study
Japanese Journal of Clinical Oncology · 2024
DOI: 10.1093/jjco/hyae086 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Kazuma Fujita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Akita University Hospital, Akita, Japan. Hauptthemen laut MEDLINE: Cachexia, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are indicators of nutritional status in cancer patients; however, the effects of baseline mGPS and PNI on the duration of administration of the ghrelin receptor agonist anamorelin, which is used to treat cachexia in patients with cancer, are unclear. This study aimed to clarify the association of mGPS and PNI with the duration of oral anamorelin administration for patients who did not have beneficial effects from anamorelin.
Methods
The attending physician determined the duration of oral anamorelin administration based on discontinuation due to cancer progression, poor efficacy, adverse events, or death.
Results
The 12-week continuation rate of oral anamorelin was 30.4%. Univariate analysis revealed that an Eastern Cooperative Oncology Group performance status (ECOG-PS) of ≥2 (P < .001), concurrent chemotherapy (P = .002), albumin level (P = .005), C-reactive protein level (P = .013), and a mGPS of 2 (P = .014) were statistically significant predictors of the 12-week continuation rate of oral anamorelin. In the multivariate analysis, a mGPS of 2 remained a significant risk factor, and the ECOG-PS and concurrent chemotherapy had no effect on the association between the mGPS and 12-week continuation rate of oral anamorelin.
Conclusion
Patients with a mGPS of 2, compared with mGPS of 0 or 1, are less likely to maintain oral anamorelin therapy, regardless of the ECOG-PS or concurrent chemotherapy. Therefore, it is necessary to consider initiating anamorelin administration at mGPS 0 or 1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Akita University Hospital, Akita, Japan.
- Department of Clinical Oncology, Akita University, Akita, Japan.
ORCID-Profile: Kazuma Fujita, Hiroyuki Shibata
Zitieren
APA
Fujita, K., Akamine, Y., Igarashi, H., Fukushi, Y., Sasaki, K., Fukuda, K., Kikuchi, M., & Shibata, H. (2024). Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae086
Vancouver
Fujita K, Akamine Y, Igarashi H, Fukushi Y, Sasaki K, Fukuda K, et al. Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae086
BibTeX
@article{Fujita2024,
author = {Fujita, Kazuma and Akamine, Yumiko and Igarashi, Haruka and Fukushi, Yayoi and Sasaki, Katsuya and Fukuda, Koji and Kikuchi, Masafumi and Shibata, Hiroyuki},
title = {Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
doi = {10.1093/jjco/hyae086}
}
EUVIMED